Amedisys - AMED Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $128.25
Forecasted Upside: 40.69%
Number of Analysts: 15
Breakdown:
2 Sell Ratings
4 Hold Ratings
9 Buy Ratings
0 Strong Buy Ratings

^$91.16 As of 01/26/2023 01:00 AM ET

▼ -0.92 (-1.00%)

1 month | 3 months | 12 months

Get New Amedisys Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for AMED and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMED

^$128.25

▲ +40.69% Upside Potential

This price target is based on 15 analysts offering 12 month price targets for Amedisys in the last 3 months. The average price target is $128.25, with a high forecast of $190.00 and a low forecast of $85.00. The average price target represents a 40.69% upside from the last price of $91.16.

Current Consensus is Hold

The current consensus among 15 contributing investment analysts is to hold stock in Amedisys. This rating has held steady since September 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
7 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

8/5/2021

0 strong buy ratings
8 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

11/3/2021

0 strong buy ratings
8 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

2/1/2022

0 strong buy ratings
9 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

5/2/2022

0 strong buy ratings
9 buy ratings
5 hold ratings
2 sell ratings

Ratings as of

7/31/2022

0 strong buy ratings
9 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

10/29/2022

0 strong buy ratings
9 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

12/28/2022

0 strong buy ratings
9 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

1/27/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
1/25/2023	Benchmark	Lower Target	Buy	$135.00 ➝ $120.00	Low
1/23/2023	Credit Suisse Group	Lower Target	Outperform	$140.00 ➝ $115.00	Low
1/19/2023	Oppenheimer	Lower Target	Outperform	$145.00 ➝ $125.00	Low
1/5/2023	SVB Leerink	Lower Target	Market Perform	$96.00 ➝ $85.00	Low
11/11/2022	Stephens	Lower Target	Equal Weight	$122.00 ➝ $106.00	Low
11/4/2022	UBS Group	Lower Target		$88.00	Low
11/4/2022	Cowen	Lower Target		$103.00	Low
11/2/2022	Jefferies Financial Group	Reiterated Rating	Buy ➝ Buy	$150.00	Low
11/1/2022	SVB Leerink	Lower Target	Market Perform	$116.00 ➝ $96.00	Low
11/1/2022	Stephens	Boost Target	Equal Weight	$105.00 ➝ $122.00	Low
10/31/2022	Royal Bank of Canada	Lower Target	Outperform	$165.00 ➝ $139.00	Low
10/28/2022	Barclays	Lower Target	Overweight	$154.00 ➝ $126.00	Low
10/28/2022	Stephens	Lower Target	Equal Weight	$120.00 ➝ $105.00	Low
10/28/2022	Truist Financial	Lower Target	Buy	$140.00 ➝ $130.00	Low
10/28/2022	Oppenheimer	Lower Target	Outperform	$175.00 ➝ $145.00	Low
10/27/2022	Raymond James	Downgrade	Outperform ➝ Market Perform		Low
10/24/2022	Deutsche Bank Aktiengesellschaft	Lower Target	Buy	$175.00 ➝ $165.00	Low
10/5/2022	Truist Financial	Lower Target	Buy	$150.00 ➝ $140.00	Low
10/3/2022	Benchmark	Lower Target	Buy	$165.00 ➝ $135.00	Low
8/9/2022	Cowen	Lower Target		$125.00	N/A
8/2/2022	UBS Group	Downgrade	Neutral ➝ Sell	$145.00 ➝ $95.00	Low
7/29/2022	Royal Bank of Canada	Lower Target		$199.00 ➝ $165.00	Low
7/29/2022	Oppenheimer	Lower Target		$200.00 ➝ $175.00	Low
7/14/2022	Truist Financial	Lower Target	Buy	$175.00 ➝ $150.00	Low
6/28/2022	Stifel Nicolaus	Initiated Coverage	Hold	$128.00	Low
6/28/2022	Jefferies Financial Group	Reiterated Rating	Buy	$200.00	Low
6/21/2022	SVB Leerink	Lower Target	Market Perform	$117.00 ➝ $107.00	Low
6/21/2022	Bank of America	Downgrade	Neutral ➝ Underperform	$145.00 ➝ $102.00	Low
6/21/2022	Deutsche Bank Aktiengesellschaft	Lower Target	Buy	$210.00 ➝ $175.00	Low
6/21/2022	Truist Financial	Lower Target	Buy	$200.00 ➝ $175.00	Low
6/21/2022	Stephens	Lower Target	Equal Weight	$155.00 ➝ $125.00	Low
5/27/2022	SVB Leerink	Lower Target	Market Perform	$131.00 ➝ $117.00	Low
4/29/2022	Oppenheimer	Reiterated Rating	Outperform	$200.00	Low
4/29/2022	Deutsche Bank Aktiengesellschaft	Lower Target		$230.00 ➝ $210.00	Medium
4/29/2022	Raymond James	Lower Target		$200.00 ➝ $180.00	Medium
4/7/2022	Jefferies Financial Group	Reiterated Rating	Buy ➝ Buy	$200.00	High
3/1/2022	UBS Group	Upgrade	Sell ➝ Neutral	$152.00 ➝ $168.00	Medium
2/25/2022	Royal Bank of Canada	Lower Target	Outperform	$221.00 ➝ $199.00	High
2/25/2022	Credit Suisse Group	Lower Target	Outperform	$200.00 ➝ $195.00	High
2/25/2022	Truist Financial	Lower Target	Buy	$210.00 ➝ $200.00	High
2/25/2022	Oppenheimer	Lower Target	Outperform	$225.00 ➝ $200.00	High
2/25/2022	Raymond James	Lower Target	Outperform	$225.00 ➝ $200.00	High
2/25/2022	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$210.00 ➝ $190.00	High
2/24/2022	Benchmark	Lower Target	Buy	$200.00 ➝ $175.00	High
2/18/2022	SVB Leerink	Boost Target	Market Perform	$145.00 ➝ $147.00	Low
12/21/2021	Barclays	Lower Target	Overweight	$236.00 ➝ $213.00	High
11/8/2021	Raymond James	Lower Target	Outperform	$250.00 ➝ $225.00	Low
11/5/2021	Deutsche Bank Aktiengesellschaft	Lower Target	Buy	$250.00 ➝ $230.00	High
11/4/2021	Stephens	Boost Target	Equal Weight	$178.00 ➝ $185.00	Low
11/4/2021	Royal Bank of Canada	Lower Target	Outperform	$244.00 ➝ $221.00	Low
11/4/2021	Credit Suisse Group	Boost Target	Outperform	$192.00 ➝ $205.00	Low
11/4/2021	BMO Capital Markets	Boost Target	Market Perform	$180.00 ➝ $200.00	Low
11/4/2021	SVB Leerink	Boost Target	Market Perform	$170.00 ➝ $181.00	Low
11/3/2021	Oppenheimer	Lower Target	Outperform	$265.00 ➝ $225.00	High
10/13/2021	Truist Financial	Lower Target	Buy	$255.00 ➝ $190.00	Medium
9/30/2021	BMO Capital Markets	Lower Target	Neutral ➝ Market Perform	$240.00 ➝ $180.00	Low
9/27/2021	SVB Leerink	Initiated Coverage	Market Perform	$170.00	Low
9/23/2021	UBS Group	Initiated Coverage	Sell	$150.00	High
9/17/2021	Oppenheimer	Reiterated Rating	Buy	$265.00	Medium
9/9/2021	Cowen	Initiated Coverage	Market Perform	$195.00	Medium
8/11/2021	Credit Suisse Group	Lower Target	Outperform	$330.00 ➝ $250.00	Medium
8/10/2021	Benchmark	Lower Target	Buy	$325.00 ➝ $235.00	Medium
8/9/2021	Raymond James	Lower Target	Outperform	$325.00 ➝ $250.00	High
8/6/2021	Stephens	Lower Target	Reduce ➝ Equal Weight	$310.00 ➝ $237.00	High
8/6/2021	Oppenheimer	Lower Target	Outperform	$325.00 ➝ $265.00	High
8/5/2021	Bank of America	Downgrade	Buy ➝ Neutral	$220.00	High
4/30/2021	Royal Bank of Canada	Boost Target	Outperform	$335.00 ➝ $350.00	High
2/23/2021	Benchmark	Boost Target	Positive ➝ Buy	$275.00 ➝ $325.00	Medium
2/8/2021	Deutsche Bank Aktiengesellschaft	Boost Target	Buy	$275.00 ➝ $340.00	Medium
1/5/2021	Truist Financial	Boost Target		$280.00 ➝ $325.00	N/A
11/3/2020	Barclays	Boost Target	Overweight	$290.00 ➝ $298.00	Medium
10/30/2020	Deutsche Bank Aktiengesellschaft	Boost Target	Buy	$260.00 ➝ $275.00	High
10/30/2020	Credit Suisse Group	Boost Target	Outperform	$246.00 ➝ $280.00	High
9/21/2020	Oppenheimer	Boost Target	Outperform	$250.00 ➝ $260.00	High
9/10/2020	Stephens	Reiterated Rating	Equal Weight	$235.00 ➝ $245.00	Medium
9/2/2020	BMO Capital Markets	Boost Target	Market Perform	$250.00 ➝ $270.00	High
8/20/2020	Barclays	Initiated Coverage	Overweight	$290.00 ➝ $290.00	High
7/30/2020	SunTrust Banks	Boost Target	Buy	$260.00 ➝ $270.00	Medium
7/30/2020	Benchmark	Boost Target	Buy	$210.00 ➝ $250.00	Medium
7/30/2020	Royal Bank of Canada	Boost Target	Outperform	$218.00 ➝ $260.00	Medium
7/30/2020	Deutsche Bank Aktiengesellschaft	Boost Target	Buy	$220.00 ➝ $260.00	Medium
7/30/2020	Raymond James	Boost Target	Outperform	$210.00 ➝ $255.00	Medium
7/29/2020	Jefferies Financial Group	Boost Target	Buy	$225.00 ➝ $250.00	Medium
7/10/2020	SunTrust Banks	Boost Target	Buy	$240.00 ➝ $260.00	Medium
6/18/2020	Benchmark	Upgrade	Hold ➝ Buy	$210.00	High
5/21/2020	SunTrust Banks	Boost Target	Buy	$225.00 ➝ $240.00	High
5/11/2020	UBS Group	Lower Target	Neutral	$208.00 ➝ $190.00	Low
5/11/2020	Raymond James	Lower Target	Outperform	$225.00 ➝ $210.00	Medium
5/10/2020	Royal Bank of Canada	Reiterated Rating	Buy	$218.00	Medium
5/7/2020	Benchmark	Downgrade	Buy ➝ Hold		High
4/27/2020	Oppenheimer	Reiterated Rating	Buy	$215.00	Medium
3/9/2020	Benchmark	Upgrade	Hold ➝ Buy	$205.00	High
2/21/2020	Stephens	Boost Target	Equal Weight	$180.00 ➝ $200.00	Low
2/21/2020	UBS Group	Boost Target	Neutral	$154.00 ➝ $208.00	Low
2/21/2020	BMO Capital Markets	Reiterated Rating	Market Perform	$215.00	Low
2/21/2020	Credit Suisse Group	Boost Target	Outperform	$206.00 ➝ $214.00	Low
2/20/2020	SunTrust Banks	Boost Target	Buy	$185.00 ➝ $225.00	Low
2/20/2020	Raymond James	Boost Target	Outperform	$200.00 ➝ $225.00	Low
1/17/2020	Credit Suisse Group	Initiated Coverage	Outperform	$206.00	Low
1/3/2020	Raymond James	Set Target	Outperform	$144.00 ➝ $200.00	Medium
12/18/2019	SunTrust Banks	Boost Target	Buy	$175.00 ➝ $185.00	Low
12/6/2019	BMO Capital Markets	Initiated Coverage	Market Perform	$170.00	Medium
11/26/2019	Bank of America	Boost Target	Buy	$170.00 ➝ $178.00	Low
11/1/2019	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$140.00 ➝ $160.00	High
10/22/2019	Stephens	Reiterated Rating	Equal Weight	$145.00	Low
10/21/2019	Stephens	Initiated Coverage	Equal Weight	$145.00	Low
9/16/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$155.00	Low
8/5/2019	Barclays	Boost Target	Equal Weight	$120.00 ➝ $125.00	High
8/2/2019	Royal Bank of Canada	Boost Target	Outperform	$150.00	Low
8/1/2019	Oppenheimer	Boost Target		$140.00 ➝ $150.00	Low
7/15/2019	Raymond James	Boost Target	Outperform	$140.00 ➝ $144.00	Medium
7/8/2019	Jefferies Financial Group	Set Target	Buy	$150.00	Low
5/2/2019	Raymond James	Upgrade	Market Perform ➝ Outperform	$140.00	High
3/21/2019	Barclays	Boost Target	Equal Weight ➝ Equal Weight	$115.00 ➝ $120.00	Low
3/1/2019	Craig Hallum	Lower Target	Hold	$132.00 ➝ $124.00	Low
3/1/2019	SunTrust Banks	Boost Target	Buy	$145.00	Low
2/5/2019	Benchmark	Downgrade	Buy ➝ Hold	$136.64	High
12/14/2018	Barclays	Initiated Coverage	Equal Weight ➝ Equal Weight	$130.00	High
11/16/2018	UBS Group	Initiated Coverage	Neutral ➝ Neutral	$126.00	Medium
10/30/2018	Benchmark	Upgrade	Hold ➝ Buy	$125.00	High
10/26/2018	Craig Hallum	Downgrade	Buy ➝ Hold	$116.00 ➝ $104.00	Medium
10/11/2018	Robert W. Baird	Boost Target	Neutral	$105.00 ➝ $120.00	High
10/11/2018	SunTrust Banks	Boost Target	Buy	$130.00	High
10/11/2018	Cantor Fitzgerald	Boost Target	Neutral	$117.00 ➝ $125.00	High
9/18/2018	Bank of America	Set Target	Buy	$139.00	Low
9/13/2018	Cantor Fitzgerald	Initiated Coverage	Neutral	$117.00	Low
8/3/2018	Royal Bank of Canada	Boost Target	Outperform	$115.00	Medium
7/3/2018	Bank of America	Upgrade	Neutral ➝ Buy	$88.00 ➝ $97.00	Medium
6/5/2018	Bank of America	Boost Target	Neutral ➝ Neutral	$73.00 ➝ $78.00	Medium
6/5/2018	Stephens	Reiterated Rating	Hold	$78.00	High
6/5/2018	Robert W. Baird	Boost Target	Neutral ➝ Neutral	$67.00 ➝ $72.00	High
5/9/2018	Craig Hallum	Boost Target	Buy	$60.00 ➝ $82.00	Low
5/8/2018	Robert W. Baird	Boost Target	Neutral ➝ Neutral	$66.00	High
3/19/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform		Low
3/1/2018	Robert W. Baird	Set Target	Neutral ➝ Hold	$60.00 ➝ $66.00	Medium
3/1/2018	Oppenheimer	Boost Target	Outperform	$68.00 ➝ $63.00	High
2/28/2018	Jefferies Financial Group	Set Target	Buy	$70.00	Medium

(Data available from 1/27/2018 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

8 very positive mentions
7 positive mentions
8 negative mentions
0 very negative mentions

Mentions as of

7/1/2022

3 very positive mentions
17 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/31/2022

4 very positive mentions
6 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

8/30/2022

1 very positive mentions
9 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

9/29/2022

7 very positive mentions
8 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

10/29/2022

7 very positive mentions
8 positive mentions
4 negative mentions
0 very negative mentions

Mentions as of

11/28/2022

5 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/28/2022

6 very positive mentions
9 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

1/27/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

Today's Range

Now: $91.16

$90.00

$92.85

50 Day Range

MA: $86.51

$80.12

$95.86

52 Week Range

Now: $91.16

$79.30

$179.91

Volume

215,640 shs

Average Volume

422,231 shs

Market Capitalization

$2.96 billion

P/E Ratio

24.57

Dividend Yield

N/A

Beta

0.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Amedisys?: The following Wall Street sell-side analysts have issued reports on Amedisys in the last year: Bank of America Co., Barclays PLC, Benchmark Co., BMO Capital Markets, Cowen Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, Stephens, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for AMED.
What is the current price target for Amedisys?: 16 Wall Street analysts have set twelve-month price targets for Amedisys in the last year. Their average twelve-month price target is $128.25, suggesting a possible upside of 40.7%. BMO Capital Markets has the highest price target set, predicting AMED will reach $190.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $85.00 for Amedisys in the next year.
View the latest price targets for AMED.
What is the current consensus analyst rating for Amedisys?: Amedisys currently has 2 sell ratings, 4 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AMED, but not buy more shares or sell existing shares.
View the latest ratings for AMED.
What other companies compete with Amedisys?: Other companies that are similar to Amedisys include LHC Group, Chemed, AdaptHealth, Addus HomeCare and Option Care Health. Learn More about companies similar to Amedisys.
How do I contact Amedisys' investor relations team?: Amedisys' physical mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider's listed phone number is (225) 292-2031 and its investor relations email address is [email protected] The official website for Amedisys is www.amedisys.com. Learn More about contacing Amedisys investor relations.

Amedisys - AMED Stock Price Target and Predictions

Analyst Price Target for AMED

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.59 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Amedisys?

What is the current price target for Amedisys?

What is the current consensus analyst rating for Amedisys?

What other companies compete with Amedisys?

How do I contact Amedisys' investor relations team?